SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
NKTR Drug delivery Company
An SI Board Since September 2005
Posts SubjectMarks Bans Symbol
507 31 0 NKTR
Emcee:  david nordic Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
332Vergote is a gynecologic surgeon subspecialised in onco cases and NOT the oncolodavid nordic16/14/2010
331FYI Vergote is a gynecologic surgeon subspecialised in onco cases and NOT the odalroi26/13/2010
330Confusing study, Mono, None of the patients met the objective response criteria.david nordic-6/11/2010
329Something else interesting in ovarian cancer. No investment play, this is Morphorkrw16/11/2010
328I wouldn't think so.rkrw-6/11/2010
327Wouldn't the fact the actual drug is already approved by the FDA give some lArthur Radley-6/10/2010
326If Robin encourages investors to think they can get approval based on open labelrkrw-6/10/2010
325"""The best cancer drug in 25 years per the lead cancer investigadavid nordic16/10/2010
324RK, I appreciate your skepticism....as you say the proof will be in the controllArthur Radley-6/10/2010
323It's highly premature and kind of absurd to think this is the best cancer drrkrw16/10/2010
322No doubt Gleevec works for CML - controls the white blood cell count. Mother in david nordic16/10/2010
321Better than Gleevec? :) NKTR ceo is expert at promotion.rkrw16/10/2010
320It was clear from Robin's presentation yesterday......NKTR holds the ace carArthur Radley-6/10/2010
319Ovarian Cancer NKTR 102 Phase IIB is being extended with 50 patients. NEKTAR is david nordic16/10/2010
318The gap open today gives a bullish trend for those who are technical with their Arthur Radley-6/10/2010
317whatisthetrend.net. Ovarian Cancer Treatment: A New Drug from Nektar Therapeuticdavid nordic-6/10/2010
316wsw.com Jefferies presentation today....CEO talks about deal criteria.......wilArthur Radley-6/9/2010
315Positive data out today on breast cancer, and Cantor was paying attention to ASCArthur Radley-6/9/2010
314Ovarian Cancer superior single cancer agent Watch NKTR tomorrow. finance.yahoodavid nordic16/6/2010
313money.cnn.com Nice plug for the stock...Arthur Radley-5/28/2010
312NKTR 102 (Pegylate Irinotecan) RECIST responses (confirmed and unconfirmed) weredavid nordic-5/21/2010
311Please join us for a Nektar-hosted investor-investigator breakfast at the 2010 Adavid nordic-5/20/2010
310NKTR-102 Phase 2 Clinical Data Accepted for Oral Presentation at 2010 ASCO AnnuaArthur Radley-5/20/2010
309Background: NKTR-102, a topoisomerase I inhibitor-polymer conjugate with reducedArthur Radley-5/20/2010
308Someone tip their hand today with the huge volume in the May $12.50 call activitArthur Radley-5/19/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News